蛋白酪氨酸磷酸酶(protein tyrosine phosphatases,PTPs)是一个结构多样的磷酸酶家族,含有高度保守的催化结构域。在植物体内,PTP主要的靶蛋白是促细胞分裂剂激活性蛋白激酶(mitogen-activated protein kinase,MAPK)。MAPK级联途径参与...蛋白酪氨酸磷酸酶(protein tyrosine phosphatases,PTPs)是一个结构多样的磷酸酶家族,含有高度保守的催化结构域。在植物体内,PTP主要的靶蛋白是促细胞分裂剂激活性蛋白激酶(mitogen-activated protein kinase,MAPK)。MAPK级联途径参与有机体的发育、细胞增殖、激素调节以及逆境胁迫的信号转导,PTP在MAPK级联途径中主要起负调控作用。本文就PTP的结构和功能、MAPK在植物中的作用及PTP在MAPK级联途径中的功能进行综述,并着重介绍PTP在拟南芥中的研究进展。展开更多
在11月初在纽约召开的 General Motors Cancer Research(美国 Genenal Motors 公司癌研究财团)会议上澳大利亚 Walter and Eliza Hall Institute 的 George Morystan 发言说:"如果要把以前使用的抗癌剂与粒细胞巨噬细胞集落刺激因...在11月初在纽约召开的 General Motors Cancer Research(美国 Genenal Motors 公司癌研究财团)会议上澳大利亚 Walter and Eliza Hall Institute 的 George Morystan 发言说:"如果要把以前使用的抗癌剂与粒细胞巨噬细胞集落刺激因子(GM-CSF)合用。展开更多
Intravenous immunoglobulin (Ig IV) has been used for many years in the treatment of primary antibody deficiencies. We performed a retrospective study of the clinical features and outcome of agammaglobulinemia children...Intravenous immunoglobulin (Ig IV) has been used for many years in the treatment of primary antibody deficiencies. We performed a retrospective study of the clinical features and outcome of agammaglobulinemia children who received prolonged IgIV infusions. Patients and methods: Ten children,9 male et 1 female, with agammaglobulinemia diagnosis were studied for the clinical manifestations before and during the IgIV replacement therapy. Serum Ig levels were quantified by nephelometry. Circulating B and T cells were counted by immunofluorescence labeling by monoclonal antibodies. T cell fonctions were assessed by using mitogen and antigen-induced T-cell proliferation assays in vitro. Patients clinical status was evaluated respectively, before initiation and at every moment (when patients had an infection) of the replacement therapy. Results: IgIV therapy was performed for 866 cumulated months, median 108 months. The median IgIV doses administered to the 10 patients was 500 mg/kg/month.Residual serum IgG mean level was 3,9 g/L. All patients had 99 bacterial infections/ year before Ig IV, mainly respiratory tract infections (48,5%), and 4 patients had bronchiectas is before Ig replacement therapy. The number of infection /year fall to 25 during IgIV replacement, and the infection/patient/year rate decreases significantly. One patient developed an Echovirus 27 meningoencephalitis during this treatment. Conclusion: IgIV therapy with residual IgG mean level of 3,9 g/l reduced significantly the rate of bacterial infections. The use of specific antibiotherapy and respiratory kinesitherapy led to a lower rate of respiratory tract infections, and the stabilisation of the bronchiectasis.However this intravenous replacement therapy does not protect against viral meningoencephalitis.展开更多
文摘蛋白酪氨酸磷酸酶(protein tyrosine phosphatases,PTPs)是一个结构多样的磷酸酶家族,含有高度保守的催化结构域。在植物体内,PTP主要的靶蛋白是促细胞分裂剂激活性蛋白激酶(mitogen-activated protein kinase,MAPK)。MAPK级联途径参与有机体的发育、细胞增殖、激素调节以及逆境胁迫的信号转导,PTP在MAPK级联途径中主要起负调控作用。本文就PTP的结构和功能、MAPK在植物中的作用及PTP在MAPK级联途径中的功能进行综述,并着重介绍PTP在拟南芥中的研究进展。
文摘在11月初在纽约召开的 General Motors Cancer Research(美国 Genenal Motors 公司癌研究财团)会议上澳大利亚 Walter and Eliza Hall Institute 的 George Morystan 发言说:"如果要把以前使用的抗癌剂与粒细胞巨噬细胞集落刺激因子(GM-CSF)合用。
文摘Intravenous immunoglobulin (Ig IV) has been used for many years in the treatment of primary antibody deficiencies. We performed a retrospective study of the clinical features and outcome of agammaglobulinemia children who received prolonged IgIV infusions. Patients and methods: Ten children,9 male et 1 female, with agammaglobulinemia diagnosis were studied for the clinical manifestations before and during the IgIV replacement therapy. Serum Ig levels were quantified by nephelometry. Circulating B and T cells were counted by immunofluorescence labeling by monoclonal antibodies. T cell fonctions were assessed by using mitogen and antigen-induced T-cell proliferation assays in vitro. Patients clinical status was evaluated respectively, before initiation and at every moment (when patients had an infection) of the replacement therapy. Results: IgIV therapy was performed for 866 cumulated months, median 108 months. The median IgIV doses administered to the 10 patients was 500 mg/kg/month.Residual serum IgG mean level was 3,9 g/L. All patients had 99 bacterial infections/ year before Ig IV, mainly respiratory tract infections (48,5%), and 4 patients had bronchiectas is before Ig replacement therapy. The number of infection /year fall to 25 during IgIV replacement, and the infection/patient/year rate decreases significantly. One patient developed an Echovirus 27 meningoencephalitis during this treatment. Conclusion: IgIV therapy with residual IgG mean level of 3,9 g/l reduced significantly the rate of bacterial infections. The use of specific antibiotherapy and respiratory kinesitherapy led to a lower rate of respiratory tract infections, and the stabilisation of the bronchiectasis.However this intravenous replacement therapy does not protect against viral meningoencephalitis.
